Thioridazine-hydrochloride-associated agranulocytosis

Area of Science:

• Pharmacology
• Hematology
• Toxicology

Background:

• Thioridazine hydrochloride is an antipsychotic medication.
• Agranulocytosis is a severe reduction in white blood cells, increasing infection risk.

Observation:

• A case of thioridazine-hydrochloride-associated agranulocytosis is presented.
• Eight prior cases are reviewed, totaling nine patients.
• No immunological markers were identified, suggesting a direct toxic effect.

Findings:

• Agranulocytosis typically manifests between 5-11 weeks of therapy.
• The complication is not dose-dependent.
• Three of nine patients died from infections.

Implications:

• Thioridazine-hydrochloride-associated agranulocytosis is a rare but severe adverse effect.
• Close monitoring for infection in patients receiving thioridazine hydrochloride is essential.
• Prompt treatment of infections is critical for patient survival.